Market Cap (In USD)
276.73 Million
Revenue (In USD)
28.56 Million
Net Income (In USD)
-28.89 Million
Avg. Volume
22.00
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 2.95-5.55
- PE
- -
- EPS
- -
- Beta Value
- 1.122
- ISIN
- FR0004163111
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. M. Pascal Prigent
- Employee Count
- -
- Website
- https://www.genfit.com
- Ipo Date
- 2014-01-27
- Details
- Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
More Stocks
-
INDB
-
SL
-
GUKYF
-
LNCLFLincoln Gold Mining Inc.
LNCLF
-
AIPArteris, Inc.
AIP
-
ANVSAnnovis Bio, Inc.
ANVS
-
1450
-
SPKTFSpectra Products Inc.
SPKTF